215 related articles for article (PubMed ID: 33775025)
1. CROSS or FLOT in Distal Esophageal and Gastroesophageal Cancer.
Karadag I; Karakaya S; Ates O; Cakmak Oksuzoglu OB
J Coll Physicians Surg Pak; 2021 Mar; 31(3):326-329. PubMed ID: 33775025
[TBL] [Abstract][Full Text] [Related]
2. RACE-trial: neoadjuvant radiochemotherapy versus chemotherapy for patients with locally advanced, potentially resectable adenocarcinoma of the gastroesophageal junction - a randomized phase III joint study of the AIO, ARO and DGAV.
Lorenzen S; Biederstädt A; Ronellenfitsch U; Reißfelder C; Mönig S; Wenz F; Pauligk C; Walker M; Al-Batran SE; Haller B; Hofheinz RD
BMC Cancer; 2020 Sep; 20(1):886. PubMed ID: 32933498
[TBL] [Abstract][Full Text] [Related]
3. FLOT or CROSS for gastroesophageal junction cancers-is the debate over yet?
Shariff B; Mehta R
Chin Clin Oncol; 2023 Jun; 12(3):24. PubMed ID: 37303220
[TBL] [Abstract][Full Text] [Related]
4. Perioperative treatment in resectable gastric cancer with spartalizumab in combination with fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT): a phase II study (GASPAR).
Dos Santos M; Lequesne J; Leconte A; Corbinais S; Parzy A; Guilloit JM; Varatharajah S; Brachet PE; Dorbeau M; Vaur D; Weiswald LB; Poulain L; Le Gallic C; Castera-Tellier M; Galais MP; Clarisse B
BMC Cancer; 2022 May; 22(1):537. PubMed ID: 35549674
[TBL] [Abstract][Full Text] [Related]
5. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial.
Al-Batran SE; Hofheinz RD; Pauligk C; Kopp HG; Haag GM; Luley KB; Meiler J; Homann N; Lorenzen S; Schmalenberg H; Probst S; Koenigsmann M; Egger M; Prasnikar N; Caca K; Trojan J; Martens UM; Block A; Fischbach W; Mahlberg R; Clemens M; Illerhaus G; Zirlik K; Behringer DM; Schmiegel W; Pohl M; Heike M; Ronellenfitsch U; Schuler M; Bechstein WO; Königsrainer A; Gaiser T; Schirmacher P; Hozaeel W; Reichart A; Goetze TO; Sievert M; Jäger E; Mönig S; Tannapfel A
Lancet Oncol; 2016 Dec; 17(12):1697-1708. PubMed ID: 27776843
[TBL] [Abstract][Full Text] [Related]
6. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial.
Al-Batran SE; Homann N; Pauligk C; Goetze TO; Meiler J; Kasper S; Kopp HG; Mayer F; Haag GM; Luley K; Lindig U; Schmiegel W; Pohl M; Stoehlmacher J; Folprecht G; Probst S; Prasnikar N; Fischbach W; Mahlberg R; Trojan J; Koenigsmann M; Martens UM; Thuss-Patience P; Egger M; Block A; Heinemann V; Illerhaus G; Moehler M; Schenk M; Kullmann F; Behringer DM; Heike M; Pink D; Teschendorf C; Löhr C; Bernhard H; Schuch G; Rethwisch V; von Weikersthal LF; Hartmann JT; Kneba M; Daum S; Schulmann K; Weniger J; Belle S; Gaiser T; Oduncu FS; Güntner M; Hozaeel W; Reichart A; Jäger E; Kraus T; Mönig S; Bechstein WO; Schuler M; Schmalenberg H; Hofheinz RD;
Lancet; 2019 May; 393(10184):1948-1957. PubMed ID: 30982686
[TBL] [Abstract][Full Text] [Related]
7. Perioperative chemotherapy with 5-FU, leucovorin, oxaliplatin, and docetaxel (FLOT) for esophagogastric adenocarcinoma: ten years real-life experience from a surgical perspective.
Sisic L; Crnovrsanin N; Nienhueser H; Jung JO; Schiefer S; Haag GM; Bruckner T; Schneider M; Müller-Stich BP; Büchler MW; Schmidt T
Langenbecks Arch Surg; 2023 Feb; 408(1):81. PubMed ID: 36763220
[TBL] [Abstract][Full Text] [Related]
8. Prognostic factors of perioperative FLOT regimen in operable gastric and gastroesophageal junction tumors: real-life data (Turkish Oncology Group).
Erol C; Sakin A; Başoğlu T; Özden E; Çabuk D; Doğan M; Öksüzoğlu B; Yıldırım HÇ; Öner İ; Eryılmaz MK; Dülgar Ö; Aydın D; Doğan N; Özen M; Hacıbekiroğlu İ; Özdemir N; Gürler F; Paksoy N; Karabulut S; Aksoy A; Hızal M; Kahraman S; Şen E; Paydaş S; Çılbır E; Fırat F; Akdeniz N; Özçelik M; Oyman A; Baytemür NK; Acar R; Almuradova E; Karabulut B; Şakalar T; Arak H; Değerli E; Türker S; Alan Ö; Er Ö; Taşçı EŞ; Demir N; Çavdar E; Turhal S; Dede DŞ; Akıncı MB; Yalçın B; Yumuk F; Yalçın Ş; Şendur MAN
Turk J Med Sci; 2022 Aug; 52(4):1022-1032. PubMed ID: 36326360
[TBL] [Abstract][Full Text] [Related]
9. Operative Results and Perioperative Morbidity After Intensified Neoadjuvant Chemotherapy with FLOT for Gastroesophageal Adenocarcinoma Impact of Intensified Neoadjuvant Treatment.
Ganschow P; Hofmann L; Stintzing S; Heinemann V; Angele M; Werner J; Schulz C
J Gastrointest Surg; 2021 Jan; 25(1):58-66. PubMed ID: 32040809
[TBL] [Abstract][Full Text] [Related]
10. Fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) regimen in the first-line treatment of metastatic gastric cancer: A single-center experience.
Tastekin D; Paksoy N; Dogan I; Ferhatoglu F; Khanmammadov N; Bozbey HU; Karabulut S
J Cancer Res Ther; 2023; 19(2):253-258. PubMed ID: 37006064
[TBL] [Abstract][Full Text] [Related]
11. Perioperative therapy with FLOT4 significantly increases survival in patients with gastroesophageal and gastric cancer in a large real-world cohort.
Möhring C; Mańczak A; Timotheou A; Sadeghlar F; Zhou T; Mahn R; Monin MB; Toma M; Feldmann G; Brossart P; Köksal M; Sarria GR; Sommer N; Lingohr P; Jafari A; Kalff JC; Strassburg CP; Gonzalez-Carmona MA
Int J Cancer; 2023 Aug; 153(3):609-622. PubMed ID: 36919950
[TBL] [Abstract][Full Text] [Related]
12. Effect of peri-operative chemotherapy regimen on survival in the treatment of locally advanced oesophago-gastric adenocarcinoma - A comparison of the FLOT and 'MAGIC' regimens.
Moore JL; Kumar S; Santaolalla A; Patel PH; Kapiris M; Van Hemelrijck M; Maisey N; Hill M; Lagergren J; Gossage JA; Kelly M; Chaudry A; Allum WH; Baker CR; Cunningham D; Davies AR;
Eur J Cancer; 2022 Mar; 163():180-188. PubMed ID: 35085931
[TBL] [Abstract][Full Text] [Related]
13. Docetaxel, Oxaliplatin, and 5-Fluorouracil (DOF) in Metastatic and Unresectable Gastric/Gastroesophageal Junction Adenocarcinoma: A Phase II Study with Long-Term Follow-Up.
Rosenberg AJ; Rademaker A; Hochster HS; Ryan T; Hensing T; Shankaran V; Baddi L; Mahalingam D; Mulcahy MF; Benson AB
Oncologist; 2019 Aug; 24(8):1039-e642. PubMed ID: 31138725
[TBL] [Abstract][Full Text] [Related]
14. Preferred neoadjuvant therapy for gastric and gastroesophageal junction adenocarcinoma: a systematic review and network meta-analysis.
Grizzi G; Petrelli F; Di Bartolomeo M; Viti M; Texeira Moraes M; Luciani A; Passalacqua R; Ghidini M; Tomasello G; Baiocchi GL; Celotti A
Gastric Cancer; 2022 Sep; 25(5):982-987. PubMed ID: 35704113
[TBL] [Abstract][Full Text] [Related]
15. EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group.
Wagner AD; Grabsch HI; Mauer M; Marreaud S; Caballero C; Thuss-Patience P; Mueller L; Elme A; Moehler MH; Martens U; Kang YK; Rha SY; Cats A; Tokunaga M; Lordick F
BMC Cancer; 2019 May; 19(1):494. PubMed ID: 31126258
[TBL] [Abstract][Full Text] [Related]
16. NeoFLOT: Multicenter phase II study of perioperative chemotherapy in resectable adenocarcinoma of the gastroesophageal junction or gastric adenocarcinoma-Very good response predominantly in patients with intestinal type tumors.
Schulz C; Kullmann F; Kunzmann V; Fuchs M; Geissler M; Vehling-Kaiser U; Stauder H; Wein A; Al-Batran SE; Kubin T; Schäfer C; Stintzing S; Giessen C; Modest DP; Ridwelski K; Heinemann V
Int J Cancer; 2015 Aug; 137(3):678-85. PubMed ID: 25530271
[TBL] [Abstract][Full Text] [Related]
17. Impact of neoadjuvant FLOT treatment of advanced gastric and gastroesophageal junction cancer following surgical therapy.
Paszt A; Simonka Z; Budai K; Horvath Z; Erdos M; Vas M; Ottlakan A; Nyari T; Szepes Z; Uhercsak G; Maraz A; Torday L; Tiszlavicz L; Olah J; Lazar G
Front Surg; 2023; 10():1148984. PubMed ID: 37077865
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and tolerability of fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in unselected patients with advanced gastric and gastroesophageal cancer: does age really matter?
Möhring C; Timotheou A; Mańczak A; Sadeghlar F; Zhou T; Mahn R; Bartels A; Monin M; Toma M; Feldmann G; Brossart P; Köksal M; Sarria GR; Giordano FA; Lingohr P; Jafari A; Kalff JC; Strassburg CP; Gonzalez-Carmona MA
J Cancer Res Clin Oncol; 2023 May; 149(5):1849-1862. PubMed ID: 35763109
[TBL] [Abstract][Full Text] [Related]
19. Results of the observational prospective RealFLOT study.
Giommoni E; Lavacchi D; Tirino G; Fornaro L; Iachetta F; Pozzo C; Satolli MA; Spallanzani A; Puzzoni M; Stragliotto S; Sisani M; Formica V; Giovanardi F; Strippoli A; Prisciandaro M; Di Donato S; Pompella L; Pecora I; Romagnani A; Fancelli S; Brugia M; Pillozzi S; De Vita F; Antonuzzo L
BMC Cancer; 2021 Oct; 21(1):1086. PubMed ID: 34625033
[TBL] [Abstract][Full Text] [Related]
20. CROSS Versus FLOT Regimens in Esophageal and Esophagogastric Junction Adenocarcinoma: A Propensity-Matched Comparison.
Donlon NE; Moran B; Kamilli A; Davern M; Sheppard A; King S; Donohoe CL; Lowery M; Cunningham M; Ravi N; Mueller C; Cools-Lartigue J; Ferri L; Reynolds JV
Ann Surg; 2022 Nov; 276(5):792-798. PubMed ID: 35876385
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
